15th week of 2013 patent applcation highlights part 29 |
Patent application number | Title | Published |
20130089524 | L. JOHNSONII LA1, B. LONGUM NCC2705 AND IMMUNE DISORDERS - The present invention generally relates to the field of probiotics, and in particular to preventing and/or treating inflammatory and infectious disorders, for example by boosting the endogenous antimicrobial defences. One embodiment of the present invention is a composition comprising a combination of | 2013-04-11 |
20130089525 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif. | 2013-04-11 |
20130089526 | Methods for Using Synthetic Triterpenoids in the Treatment of Bone or Cartilage Diseases or Conditions - The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. | 2013-04-11 |
20130089527 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 2013-04-11 |
20130089528 | COMPOSITIONS AND METHODS FOR PRESERVING INSULIN-PRODUCING CELLS AND INSULIN PRODUCTION AND TREATING DIABETES - Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.1 can result in lowering of blood glucose levels and may reducing insulin resistance, the compositions, methods and cells described herein can also be used for treating Type 2 diabetes (T2D). | 2013-04-11 |
20130089529 | AGENT FOR OSTEOGENESIS USING SUBSTANCE-P AND PREPARATION PROCESS THEREOF - The present invention relates to an agent for osteogenesis containing as an active ingredient mesenchymal stem cells (MSCs) that have been mobilized from bone marrow into blood by administration of Substance-P; and a process of preparing the agent. | 2013-04-11 |
20130089530 | METHODS AND COMPOSITIONS FOR TREATING PARASITIC WORM INFECTIONS IN A MAMMAL - The invention relates to compositions for treating parasitic worm infections in a mammal. The composition includes an amount of intracellular components of lysed, beneficial, soil-inhabiting yeast cells sufficient to treat parasitic worm infections in a mammal; and/or an amount of whole or lysed soil-inhabiting bacteria cells, wherein the amount is sufficient to treat parasitic worm infections in a mammal, and optionally a pharmaceutically suitable carrier. | 2013-04-11 |
20130089531 | METHOD FOR INHIBITION OF BLOOD PHOSPHORUS LEVEL ELEVATION - The present invention provides a method for inhibiting blood phosphorus level elevation, including administering to a patient in need thereof a composition comprising a lactic acid bacterium as an active ingredient. The method may further include encapsulating the composition comprising a lactic acid bacterium in a capsule. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administrable, and can sufficiently inhibit a blood phosphorus level elevation. | 2013-04-11 |
20130089532 | ADIPONECTIN PRODUCTION ACCELERATING COMPOSITION - A problem to be solved is to provide an orally ingestible composition which promotes the production of adiponectin and which is free from safety issues such as side effects and toxicity. An adiponectin production promoting composition is prepared which comprises salmon milt extract, brewer's yeast extract, avian collagen, and yeast containing mineral and having an adiponectin production promoting activity. Preferably, the salmon milt extract comprises low molecular weight components obtained by enzymatic degradation of salmon milt into oligonucleotides and oligopeptides. Preferably, the brewer's yeast extract comprises 50 to 80% of RNA. Preferably, the mineral yeast comprises, in dry yeast, 2 to 3% of zinc, 0.3 to 0.5% of copper, and 0.01 to 0.02% of selenium. Preferably, the adiponectin production promoting composition comprises 16 to 17 parts by mass of the brewer's yeast extract, 33 to 34 parts by mass of the avian collagen, and 22 to 23 parts by mass of the yeast containing mineral per 100 parts by mass of the salmon milt extract. | 2013-04-11 |
20130089533 | DISINFECTANT COMPOSITIONS WITH HYDROGEN PEROXIDE - Disinfectant compositions include 0.001 to 10% by weight of hydrogen peroxide or a hydrogen peroxide source based on the total weight of the composition; 0.001 to 20% by weight of at least one amphoteric surfactant based on the total weight of the composition; and 0.001 to 15% by weight of at least one alkali metal or alkaline earth metal salt of a cyclic or heterocyclic aromatic compound comprising at least one hydroxyl group, carboxylic group, or combination thereof based on the total weight of the composition. The disinfectant compositions are particularly effective at treating surfaces contaminated with resistant bacteria, such as | 2013-04-11 |
20130089534 | METHODS FOR ASSISTING ANTI-CANCER DRUGS - A method for assisting an anti-cancer drug comprising administrating an effective amount of | 2013-04-11 |
20130089535 | AGENT FOR REDUCING ACETALDEHYDE IN ORAL CAVITY - Disclosed herein is a novel enzymatic agent effective in reducing acetaldehyde in the oral cavity. It has been found that an aldehyde dehydrogenase derived from a microorganism belonging to the genus | 2013-04-11 |
20130089536 | PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT - The present invention relates to a GCP II (glutamate carboxypeptidase II) mutant (K699S) having the activity of inhibiting glutamate production and the activity of cleavaging β-amyloid, and to a pharmaceutical composition for the prevention and treatment of a disease selected from the group consisting of amyloidosis, Alzheimer's disease, Down syndrome accompanying Alzheimer's disease, stroke, dementia, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease comprising the GCP II mutant (K699S) as an active ingredient. The GCP II (glutamate carboxypeptidase II) mutant (K699S) demonstrates not only excellent Aβ cleavage activity compared with the wild type GCP II but also excellent activity of inhibiting glutamate production, unlike the wild type GCP II, so that the mutant has been confirmed to have higher effect and stability than the wild type, suggesting that the GCP II mutant can be effectively used for the prevention or treatment of neurodegenerative diseases. | 2013-04-11 |
20130089537 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 - This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation. | 2013-04-11 |
20130089538 | TREATING CANCER BY MODULATING MAMMALIAN STERILE 20-LIKE KINASE 3 - The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods. | 2013-04-11 |
20130089539 | KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS - Compositions and methods for treating Th2- and Th1-mediated disease are provided. | 2013-04-11 |
20130089540 | New Humanized Anti-CD20 Monoclonal Antibody - The present invention discloses methods of design and preparation for a new humanized anti-CD20 monoclonal antibody, related genes, protein sequence, and the use of said antibody. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect. | 2013-04-11 |
20130089541 | Antibodies with Enhanced or Suppressed Effector Function - Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components. | 2013-04-11 |
20130089542 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. | 2013-04-11 |
20130089543 | MONOCLONAL ANTIBODIES THAT BIND OR NEUTRALIZE DENGUE VIRUS - The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2013-04-11 |
20130089544 | Antibodies Directed to ERBB2 - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention | 2013-04-11 |
20130089545 | NOVEL COMPOUNDS AND THEIR EFFECTS ON FEEDING BEHAVIOUR - The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity. | 2013-04-11 |
20130089546 | THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal. | 2013-04-11 |
20130089547 | Hybrid Constant Regions - The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89. | 2013-04-11 |
20130089548 | METHOD AND COMPOSITIONS TO INDUCE APOPTOSIS OF TUMORAL CELLS EXPRESSING SHH - A method for inducing apoptosis of tumoral cells in a patient having cancer cells bearing Cell-adhesion molecule-related/Downregulated by Oncogenes (CDO) receptors and expressing Sonic Hedgehog (SHH), including administering to the patient an effective amount of an agonist of CDO's apoptotic function, wherein the agonist is selected from the group consisting of a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, and an siRNA which is capable of inhibiting SHH expression, and related CDO fragments, fusion proteins comprising a CDO fragment, antibodies against SHH, and siRNAs which are capable of inhibiting SHH expression. | 2013-04-11 |
20130089549 | B CELL ACTIVATING FACTOR ANTAGONIST AND PREPARATION METHOD AND USE THEREOF - The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases. | 2013-04-11 |
20130089550 | NOVEL CTLA4-IG IMMUNOADHESINS - The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes. | 2013-04-11 |
20130089551 | TREATMENT OF PULMONARY EDEMA - The invention relates to a method of treatment of pulmonary edema, comprising the step of administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis or inhibiting VEGF-D activity in the subject. The method may comprise the step of identifying a subject at risk of developing pulmonary edema. The invention also relates to an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity for treating pulmonary edema in a subject. Further, the invention relates to use of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity in the manufacture of a medicament for treating pulmonary edema in a subject. | 2013-04-11 |
20130089552 | ACYLGLYCEROL ACYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds. | 2013-04-11 |
20130089553 | METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins, heteromultimers and antibody-immunoadhesin chimeras. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. | 2013-04-11 |
20130089554 | RON Binding Constructs and Methods of Use Thereof - This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders. | 2013-04-11 |
20130089555 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2013-04-11 |
20130089556 | ANTI C-MET HUMANIZED ANTIBODY AND USES THEREOF - An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided. | 2013-04-11 |
20130089557 | ANTIBODY SPECIFICALLY BINDING TO EPITOPE IN SEMA DOMAIN OF C-MET - An antibody or antigen binding fragment thereof that specifically binds to an epitope in a SEMA domain of c-Met protein, and pharmaceutical compositions, methods, kits, nucleic acids, and cells related thereto. | 2013-04-11 |
20130089558 | DENGUE AND WEST NILE VIRUSES PROTEINS AND GENES CODING THE FOREGOING, AND THEIR USE IN VACCINAL, THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications. | 2013-04-11 |
20130089559 | BINDING MEMBERS FOR HUMAN CYTOMEGALOVIRUS - The invention relates to binding members, especially antibody molecules, which may neutralise the biological effects of human cytomegalovirus (hCMV). The binding members may be useful for the treatment and prophylaxis of hCMV infection. | 2013-04-11 |
20130089560 | BONE MORPHOGENETIC PROTEIN RECEPTOR BINDING AGENTS AND METHODS OF THEIR USE - The present invention provides bone morphogenetic protein receptor (BMPR) binding agents, such as antibodies, and compositions comprising said binding agents. The binding agents are useful to treat diseases such as cancer. | 2013-04-11 |
20130089561 | EPITOPE REGIONS OF A THYROTROPHIN (TSH) RECEPTOR, USES THEREOF AND ANTIBODIES THERETO - The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto. | 2013-04-11 |
20130089562 | METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS - Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease. | 2013-04-11 |
20130089563 | METHOD OF DIAGNOSING AND TREATING CANCER - A method of diagnosing and treating a glioma or a breast cancer is disclosed. The method of diagnosing comprises analyzing an amount or activity of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) in a brain or breast cell sample of the subject, wherein an up-regulation in an amount or activity of hnRNP A2/B1 beyond a predetermined threshold with respect to a control cell sample is indicative of the breast cancer or glioma. The method may also be used for staging the cancer and for predicting patient's prognosis of survival. The method of treating glioblastoma and metastatic breast cancer includes inhibiting the expression and/or activity of hnRNP A2/B1. | 2013-04-11 |
20130089564 | Therapeutic Uses of Glandular Kallikrein - Provided is an immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, having the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Also provided are methods and compositions for Using K1 peptides in the treatment of autoimmune diseases. | 2013-04-11 |
20130089565 | IMMUNE PRIVILEGED AND MODULATORY PROGENITOR CELLS - Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like. | 2013-04-11 |
20130089566 | VACCINE PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES - The present invention discloses a vaccine preventing and/or treating autoimmune diseases. Its active component is: the mixture consisting of a protein antigen causing an autoimmune disease or the epitope polypeptides thereof, and the recombinant eukaryotic vector with the coding genes of an autoantigen or the epitope polypeptides thereof inserted into multiple cloning sites. The autoantigen is insulin, glutamic acid decarboxylase or heat shock protein, myelin oligodendrocyte glycoprotein, two myelin antigens, zona pellucida 3, myoglobulin, type II collagen, thyroglobulin, cell membrane surface antigen, type II colloid antigen, acetylcholine receptor, thyrocyte cell surface antigen, salivary gland duct antigen, thyroglobulin, superantigen, or interphotoreceptor retinoid binding protein. The vaccine can inhibit the proliferation of T cells of immune animals and humans, induce the occurrence of immune suppression, as well as prevent and/or treat autoimmune diseases effectively. | 2013-04-11 |
20130089567 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS - The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus. | 2013-04-11 |
20130089568 | HAIR GROWTH STIMULATOR BASED ON ECKLONIA CAVA EXTRACT, PREPARATION METHOD THEREOF, AND COSMETIC COMPOSITION CONTAINING THE SAME - The present invention relates to a hair growth stimulator based on an | 2013-04-11 |
20130089569 | RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS - The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA. | 2013-04-11 |
20130089570 | ORAL VACCINE COMPROMISING AN ANTIGEN AND A TOLL-LIKE RECEPTOR AGONIST - The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition. | 2013-04-11 |
20130089571 | Vaccine - The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions. | 2013-04-11 |
20130089572 | Partially Hydrolyzed Casein-Whey Nutritional Compositions For Reducing The Onset Of Allergies - The present disclosure relates to methods of reducing the onset of allergies. In certain embodiments, the method includes administering to an infant a nutritional composition that includes a fat or lipid source, a carbohydrate source, a protein source comprising whey and casein proteins and, optionally, a probiotic. In certain embodiments, the whey:casein ratio in the protein source is from about 50:50 to about 70:30 and the degree of hydrolysis of the proteins included in the protein source is from about 4% to about 10%. | 2013-04-11 |
20130089573 | NOVEL PROCESS - The present invention provides processes for the production of a submicron oil in water emulsion comprising the steps of preparing a submicron oil in water emulsion; pre-filtering the oil in water emulsion through a first sterile grade filter and again filtering the oil in water emulsion through a second sterile grade filter. | 2013-04-11 |
20130089574 | METHOD OF PREVENTIVE ON-DEMAND HORMONAL CONTRACEPTION - The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse. | 2013-04-11 |
20130089575 | Pharmaceutical methods and topical compositions containing acitretin - The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis. | 2013-04-11 |
20130089576 | IMPLANTABLE EMBOLIC SCAFFOLDS THAT PROMOTE HEALING - Implant devices and structures that reduce inflammation and promote healing of the area of implant. Specifically, the use of shape memory open cell biocompatible polymer foams for implants that assist in and promote healing and especially in filling and sealing aneurisms. | 2013-04-11 |
20130089577 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS - Described herein are compositions (e.g., a pharmaceutical composition) and methods for controlling the delivery of a therapeutic agent, and their use in the treatment and/or prevention of diseases and disorders. | 2013-04-11 |
20130089578 | LIQUID INSECTICIDE INCLUDING DIATOMACEOUS EARTH - An insecticide including diatomaceous earth in a liquid mixture of water and one or more additives is provided. The diatomaceous earth may be present in an amount between at least 20 and less than 25 weight percent of the insecticide. The insecticide is applied in liquid form to surfaces for controlling the spread of insects. The liquid component of the insecticide evaporates leaving a thin layer of the dried diatomaceous earth. Insects traversing the diatomaceous earth layer are scratched and scraped by the layer, which results in water loss from the exoskeleton and eventually death. | 2013-04-11 |
20130089579 | Combination of Hyaluronic Acid and Prilocaine - A composition of matter comprising hyaluronic acid and/or a pharmaceutically acceptable hyaluronate salt, cross-linked hyaluronic acid and/or a pharmaceutically acceptable cross-linked hyaluronate salt, and prilocalne and/or a pharmaceutically acceptable salt thereof, and optionally at least one additive. | 2013-04-11 |
20130089580 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2013-04-11 |
20130089581 | SKIN-FRIENDLY ADHESIVES FROM POLYALKLETHER-BASED PHOTOINITIATORS - The invention provides a method for manufacturing a skin-friendly pressure-sensitive adhesive composition, said method comprising the steps of: a. providing a matrix composition comprising a polymeric photoinitiator of the general formula (I): R | 2013-04-11 |
20130089582 | HYDROPHILIC GELS FROM POLYURETHANE-BASED PHOTOINITIATORS - The present invention relates to the use of polymeric photoinitiators based on polyalkyletherurethane backbones in the production of hydrophilic gels, in particular hydrogels. The invention relates to methods for manufacturing hydrophilic gels using said polymeric photoinitiators, and the hydrophilic gels thus obtained. | 2013-04-11 |
20130089583 | HAIR COLORATION COMPOSITIONS EXHIBITING PREDETERMINED STRUCTURAL COLORATION THROUGH PHOTONIC BAND GAP EFFECTS - Hair coloration compositions for application to hair are provided. In an embodiment, a hair coloration composition includes a plurality of particles. Each particle comprises a first layer of first material and a first layer of second material with an interface therebetween. The first material has a first refractive index and the second material has a second refractive index. The difference between the first refractive index and the second refractive index is greater than zero. Each particle is configured to exhibit a photonic band gap effect at the interface when exposed to incident white light. | 2013-04-11 |
20130089584 | COSMETIC METHOD OF MODIFYING THE APPEARANCE OF THE OUTLINE OF THE EYE - A method of cosmetically modifying the appearance of the outline of the eye, the method including the step consisting in applying at least one patch on the movable upper eyelid, the application face of the patch having a predefined non-plane shape with multi-directional curvature, or at least one patch made of a material suitable for responding to stress by deforming in non-elastic manner as to take up multi-directional curvature on the eyelid and conserve the curvature when the stress ceases. | 2013-04-11 |
20130089585 | FILLER COMPRISING BEADS - The present invention pertains to a filler comprising beads wherein said beads comprise a polyanionic biopolymer and divalent cations and wherein said polyanionic biopolymer is not alginate. Further, the present invention pertains to a process for manufacturing the claimed filler, and to an injection device comprising the filler. | 2013-04-11 |
20130089586 | Method of Achieving Improved Hair Feel - A method of achieving improved hair feel. The method comprises applying to hair a composition comprising: (a) a specific cationic guar polymer; (b) a specific cationic copolymer; (c) an anti-dandruff active; (d) a cosmetically acceptable carrier; (e) a surfactant; wherein the weight ratio of (a):(b) is from about 1000:1 to about 3.5:1; and wherein the sum of (a)+(b) is an amount of from about 0.0001% to about 0.7%, by total weight of the composition. The composition forms coacervate particles upon dilution of the composition with water and the coacervate particles have a squeeze flow viscosity of from about 1 cP to about 100 cP. The percentage of coacervate particles with a floc size of greater than about 20 micron is from about 1% to about 60% and the on-scalp deposition of the anti-dandruff active is at least about 1 microgram/cm | 2013-04-11 |
20130089587 | Personal Care Compositions and Methods of Making Same - The present invention relates to a personal care composition and methods of using the same, the composition including an anionic surfactant, a cationic conditioning polymer, and a silicone emulsion wherein a total content of a cyclic polysiloxane having a general formula: | 2013-04-11 |
20130089588 | FOAMABLE SUNSCREEN FORMULATION - The present application relates to sunscreen formulations, including foamable sunscreen formulations, that comprise zinc oxide and titanium dioxide particles, suitably in the size range of about 1-100 nm. The compositions suitably produce a minimal residual whitening effect when applied to a skin surface. | 2013-04-11 |
20130089589 | COMBINATION OF ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS - A combination of active substances for cosmetic preparations contains hyaluronic acid and at least one of its derivatives. At least 10 percent by weight is used in long-chain form with a molecular weight of at least 1,000,000 daltons. At least 2 percent by weight is used in short-chain form with a molecular weight not more than 200,000 daltons. | 2013-04-11 |
20130089590 | Process for Producing Microcapsules - The application describes a process for producing microcapsules which contain a shell made of polyurea and which surround in their interior a fragrance oil core, where the shell is obtained by the reaction of two structurally different diisocyanates in emulsion form. | 2013-04-11 |
20130089591 | Compositions - Polyurea and polyamide capsules encapsulating fragrance oils, which oils contain precursors of fragrant aldehydes that are adapted to release the aldehydes under activating conditions. | 2013-04-11 |
20130089592 | METHOD OF PRODUCING A HYDROGEL - The invention provides a method of enzymatically modifying xylan by selectively removing glucuronic acid and/or arabinose side chains from the xylan with a-D-glucuronidase and/or a-L-arabinofuranosidase, and allowing the modified xylan to form into a hydrogel when the xylan becomes insoluble. A bioactive substance, such as a protein, enzyme, antimicrobial agent, bactericide or pharmaceutical compound can be added to the xylan so that the substance is encapsulated within the hydrogel or incorporated onto its surface. The hydrogel can be used as a drug delivery agent, such as for sustained-release or targeted drug delivery, rectal drug delivery or a dressing for a wound, burn or scar. The hydrogel can also be used as a coating, such as on medical gloves, catheters, surgical drainage systems, utensils or the like, or can be used in a scaffold for tissue engineering. | 2013-04-11 |
20130089593 | ANTIMICROBIAL COMPOSITIONS AND METHODS EMPLOYING SAME - An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment. | 2013-04-11 |
20130089594 | MACROPOROUS BIOENGINEERED SCAFFOLDS FOR CELL TRANSPLANTATION - The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets. | 2013-04-11 |
20130089595 | Controlled Release Formulations - The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body. | 2013-04-11 |
20130089596 | COMPOSITIONS AND METHODS OF MAKING AND USING INFLUENZA PROTEINS - The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus. | 2013-04-11 |
20130089597 | MicroRNA-130a,b as a Tumor Suppressor and Sensitizing Agent for Chemotherapy - The present invention provides a method of improving a therapeutic response to a cancer treatment, in a subject, the method comprising administering an effective amount of an agent that enhances the expression of microRNA-130 or an agent that mimics the effects of microRNA-130. Further provided is a method of treating a cancer in a subject in need of such treatment comprising the step of administering an effective amount of a microRNA-130 or an agent that enhances the expression of microRNA-130. | 2013-04-11 |
20130089598 | METHOD OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. | 2013-04-11 |
20130089599 | NANO-ENCAPSULATED THERAPEUTICS FOR CONTROLLED TREATMENT OF INFECTION AND OTHER DISEASES - This invention relates to a method to provide immediate, direct and controlled time release of an effective amount of therapeutics to a wound site for a prolonged period. The pharmaceutical formulation comprising a plurality of nanoparticles, said nanoparticles encapsulating a therapeutically effective amount of one or more antibacterial agents, and an application of the formulation to an implant before surgery provide for extended release of said antibacterial agents. | 2013-04-11 |
20130089600 | CANNABINOID FORMULATIONS - The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications. | 2013-04-11 |
20130089601 | METHOD FOR TREATING ATHEROSCLEROSIS - The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector. | 2013-04-11 |
20130089602 | ENCAPSULATED CHELATOR - An enhanced chelator includes a chelating agent and a volatile material encapsulated in a biologically benign microcapsule. The enhanced chelator possesses significantly improved shelf-life in aqueous biological buffer solutions because the chelating agent is encapsulated in the microcapsule and, therefore, separated from solution components with which the chelating agent would react. The enhanced chelator is activated at a predetermined elevated temperature defined by the boiling point of the volatile material. At this predetermined elevated temperature, the volatile material exerts a vapor pressure sufficient to rupture the microcapsule and thereby release the chelating agent from the microcapsule. In one embodiment, a manganese chelator such as ethylene glycol tetraacetic acid (EGTA) is solubilized in ethanol and encapsulated in a poly(lactic-co-glycolide) (PLGA) microsphere. Upon heating to 80° C., ethanol boils within the PLGA microsphere and undergoes several orders of magnitude volume change, thereby rupturing the PLGA microsphere and releasing EGTA. | 2013-04-11 |
20130089603 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND OBESITY-RELATED CONDITIONS - A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone. | 2013-04-11 |
20130089604 | Solid Oral Dosage Form Containing An Enhancer - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 2013-04-11 |
20130089605 | Method for Preparation of Highly Pure Asiaticoside Composition from Centella Asiatica and a Method of Use Thereof - Disclosed is a commercially viable asiaticoside composition having at least 99% purity that is derived from plant | 2013-04-11 |
20130089606 | METHODS AND COMPOSITIONS FOR ORAL PHARMACEUTICAL THERAPY - It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5. | 2013-04-11 |
20130089607 | ONCE DAILY TROSPIUM CHLORIDE TREATMENT METHOD - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C | 2013-04-11 |
20130089608 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs - The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions. | 2013-04-11 |
20130089609 | CONTROLLED RELEASE NUCLEATED TABLET - Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer. | 2013-04-11 |
20130089610 | R(+)-N-METHYL-PROPARGYL-AMINOINDAN - The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof. | 2013-04-11 |
20130089611 | RASAGILINE CITRAMIDE - The subject invention provides rasagiline citramide and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of rasagiline citramide or a salt thereof. | 2013-04-11 |
20130089612 | R(+)-N-FORMYL-PROPARGYL-AMINOINDAN - The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan. | 2013-04-11 |
20130089613 | Compounds Having Activating Effect on Subtypes of Peroxisome Proliferator-Activated Receptors and its Preparation Method and Uses - Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPARα,δ,γ) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPARα,δ,γ). | 2013-04-11 |
20130089614 | Magnetic Nanoparticles and Uses Thereof - Magnetic nanoparticles are provided that have a superparamagnetic core and a nanoporous silica shell surrounding the core. The shell is functionalized with amine or S-nitrosothiol groups both inside and outside the nanopores. A process to provide such nanoparticles involves hydrolyzing tetraethoxysilane (TEOS) in a microemulsion of a superparamagnetic nanoparticle to form a superparamagnetic nanoparticle encapsulated by an incompletely hydrolyzed nanoporous silica shell, and hydrolyzing an amine-containing compound or a thiol-containing compound in situ in the presence of the incompletely hydrolyzed nanoporous silica shell before hydrolysis and densification of the silica shell is complete to functionalize the nanoporous silica shell with amine or thiol groups both inside and outside the nanopores and to maintain nanoporosity of the shell. Such magnetic nanoparticles are useful as carriers for chemical or biological species, particularly for magnetic resonance imaging, optical imaging, targeted drug delivery, cell delivery and magnetic separation applications. | 2013-04-11 |
20130089615 | Compositions of Jasmonate Compounds and Methods of Use - The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions. | 2013-04-11 |
20130089616 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS FOR USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 2013-04-11 |
20130089617 | CRYSTALLINE MICROPARTICLES OF A BETA-AGONIST COATED WITH A FATTY ACID - Crystalline microparticles consisting of a phenylalkylamino beta | 2013-04-11 |
20130089618 | Linseed Salve - Linseed Salve is a soothing, healing, all natural salve utilizing comfrey to heal, plantain to draw out the wound, mugwort as a nervine, calendula as a blood, moving diaphoretic and oils for their blood moving and drying abilities to clear old blood, and depleted, dried cells.
| 2013-04-11 |
20130089619 | METHODS FOR TREATING GLUCOSE METABOLIC DISORDERS - In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof. | 2013-04-11 |
20130089620 | COMPOSITION COMPRISING A SOLID STATE HYPOTHIOCYANITE SALT OF A CATION - A solid composition is provided herein comprising at least one hypothiocyanite salt (OSCN—) of a cation in an amorphous and/or crystalline powder form. Also provided herein are methods of making the composition and methods of treating various conditions, such as airborne infection, lower respiratory tract infection or upper respiratory tract infection. | 2013-04-11 |
20130089621 | DISINFECTANT COMPOSITIONS WITH HYDROGEN PEROXIDE - Disinfectant compositions include 0.001 to 10% by weight of hydrogen peroxide or a hydrogen peroxide source based on the total weight of the composition; 0.001 to 20% by weight of at least one amphoteric surfactant based on the total weight of the composition; and 0.001 to 0.8% by weight of at least one alkali metal or alkaline earth metal salt of a cyclic or heterocyclic aromatic compound comprising at least one hydroxyl group, carboxylic group, or combination thereof based on the total weight of the composition. The disinfectant compositions are particularly effective at treating surfaces contaminated with resistant bacteria, such as | 2013-04-11 |
20130089622 | PESTICIDAL COMPOSITIONS - This document discloses molecules having the following formula (“Formula I”): | 2013-04-11 |
20130089623 | Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates - The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein. | 2013-04-11 |